Abstract
In the course of the last 2 yr, a tremendous amount of controversy has been raised over dangers accompanying the use of the antibiotic clindamycin. The controversy has been stimulated by recent reports of fatalities from pseudomembranous colitis associated with clindamycin therapy. Varying greatly in degree of severity, the colitis has been reported in as high as 10% of all patients using the drug. The pertinence of such data in a young, healthy acne population receiving small maintenance doses is questionable. Nevertheless, because of these reports, the use of clindamycin in the treatment of many of the conditions for which it was previously considered indicated, including acne, is being seriously reevaluated.

This publication has 4 references indexed in Scilit: